tiprankstipranks
Avecho Begins Landmark Insomnia Treatment Trial
Company Announcements

Avecho Begins Landmark Insomnia Treatment Trial

Avecho Biotechnology Limited (AU:AVE) has released an update.

Pick the best stocks and maximize your portfolio:

Avecho Biotechnology Limited has launched a Phase III clinical trial for its novel oral CBD TPM-enhanced soft-gel capsule aimed at treating insomnia, marking a significant step towards potentially becoming the first over-the-counter CBD-based insomnia treatment in Australia. The study, which is the largest of its kind, will involve 519 patients across multiple cities, testing nightly doses of CBD over an 8-week period. The trial’s success would enable the company to apply for pharmaceutical registration and capitalize on recent regulatory changes allowing over-the-counter sales of CBD products in Australia.

For further insights into AU:AVE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskAvecho Biotechnology Updates on Director Interests
TipRanks Australian Auto-Generated NewsdeskAvecho Biotechnology Expands Trials and Manufacturing
TipRanks Australian Auto-Generated NewsdeskAvecho Biotech Reports Decreased Revenue and Rising Losses
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App